Surveillance study on the tolerability and safety of Flebogamma®DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients-Reference-Cited by-同舟云学术

Surveillance study on the tolerability and safety of Flebogamma®DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients

Published:2017-08-25 Issue:5 Volume:5 Page:e00345
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacol Res Perspect

Author:

Alsina Laia¹,Mohr Andreas²,Montañés Maria³,Oliver Xènia³,Martín Esperanza⁴,Pons Jaime⁵,Drewe Elizabeth⁶,Papke Jens⁷,Günther Georg⁸,Chee Ronnie⁹,Gompels Mark¹⁰,

Affiliation:

1. Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu; Institut de Recerca Pediàtrica Hospital Sant Joan de Déu, Passeig de Sant; Joan de Déu 2 08950 Esplugues de Llobregat Barcelona Spain

2. Hematology and Oncology; OncoResearch Lerchenfeld, Lerchenfeld 14 22081 Hamburg Germany

3. Pharmacovigilance Department; Instituto Grifols S.A.; Avinguda de la Generalitat 152-158 08174 Sant Cugat del Vallès, Barcelona Spain

4. Pneumology Service; Hospital Sant Joan de Déu; Fundació Althaia. Carrer Dr. Joan Soler, s/n 08243 Manresa Spain

5. Immunology Service; Hospital Son Espases; Carrer de Valldemossa 79 07120 Palma de Mallorca Spain

6. Clinical Immunology and Allergy Department; Nottingham University Hospitals - QMC Campus; Hucknall Road Nottingham NG5 1PB UK

7. Practice and Day Clinic for Internal Medicine and Oncology; Rosa-Luxemburg-Straße 6 01844 Neustadt in Sachsen Germany

8. Medical Healthcare Centre for Blood and Cancer Diseases; Kurfürstenstraße 20 D-14467 Potsdam Germany

9. Clinical Immunology Department; Royal Free London NHS Foundation Trust; 17 Lyndhurst Gardens London NW3 5NU UK

10. Immunology and Allergy Department; Southmead Hospital; Dorian Way Westbury-on-Trym Bristol BS10 5NB UK

Funder

Grifols

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Reference47 articles.

1. Factors affecting the development of adverse drug reactions;Alomar;Saudi. Pharm. J.,2014

2. Clinical and investigational considerations for the use of IGIV therapy;Ballow;Am. J. Health Syst. Pharm.,2005

3. Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease;Ballow;Clin. Exp. Immunol.,2009

4. Flebogamma® DIF: a highly purified intravenous immunoglobulin;Ballow;Pharmacy Practice News,2011

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer's disease in the AMBAR study;Journal of Clinical Apheresis;2022-10-28

2. Low‐ versus high‐concentration intravenous immunoglobulin for children with Kawasaki disease in the acute phase;International Journal of Rheumatic Diseases;2022-03-08

3. Neuropsychological, neuropsychiatric, and quality‐of‐life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study;Alzheimer's & Dementia;2021-11-02

4. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study;Alzheimer's & Dementia;2020-07-27

5. Currently available intravenous immunoglobulin (Gamunex®-C and Flebogamma® DIF) contains antibodies reacting against SARS-CoV-2 antigens;2020-04-10